To investigate the role of hepatic SAMHD1 in HCC initiation, a longitudinal study was conducted at 4, 6, 8, and 12 months post‐DEN injection, tumorigenesis rates were found to be comparable between the HKO and control groups, indicating that SAMHD1 deficiency in hepatocytes did not significantly affect the initiation of DEN‐induced hepatocarcinogenesis (Figure 4J). The gene discussed is SAMHD1; the disease is hepatocellular carcinoma.